valuation, page-14

Thanks for the response, 2ic.

I did see some of your other posts, and hence the issue of sulphuric acid - but you are not the only contributor (as various news items relating to MRE attest to).

So in the current scenario the best advice seems to be that CMR will struggle to make positive cashflow in the next 6 months (on oxides), and December quarterly will show a negative result, which would surely disappoint the market again.

And the sulphides valuation is another unanswered issue!